Research article Topical Sections

Chronic treatment with escitalopram and venlafaxine affects the neuropeptide S pathway differently in adult Wistar rats exposed to maternal separation

  • Received: 13 June 2022 Revised: 20 August 2022 Accepted: 05 September 2022 Published: 13 September 2022
  • Neuropeptide S (NPS), which is a peptide that is involved in the regulation of the stress response, seems to be relevant to the mechanism of action of antidepressants that have anxiolytic properties. However, to date, there have been no reports regarding the effect of long-term treatment with escitalopram or venlafaxine on the NPS system under stress conditions.

    This study aimed to investigate the effects of the above-mentioned antidepressants on the NPS system in adult male Wistar rats that were exposed to neonatal maternal separation (MS).

    Animals were exposed to MS for 360 min. on postnatal days (PNDs) 2–15. MS causes long-lasting behavioral, endocrine and neurochemical consequences that mimic anxiety- and depression-related features. MS and non-stressed rats were given escitalopram or venlafaxine (10mg/kg) IP from PND 69 to 89. The NPS system was analyzed in the brainstem, hypothalamus, amygdala and anterior olfactory nucleus using quantitative RT-PCR and immunohistochemical methods.

    The NPS system was vulnerable to MS in the brainstem and amygdala. In the brainstem, escitalopram down-regulated NPS and NPS mRNA in the MS rats and induced a tendency to reduce the number of NPS-positive cells in the peri-locus coeruleus. In the MS rats, venlafaxine insignificantly decreased the NPSR mRNA levels in the amygdala and a number of NPSR cells in the basolateral amygdala, and increased the NPS mRNA levels in the hypothalamus.

    Our data show that the studied antidepressants affect the NPS system differently and preliminarily suggest that the NPS system might partially mediate the pharmacological effects that are induced by these drugs.

    Citation: Miłosz Gołyszny, Michał Zieliński, Monika Paul-Samojedny, Artur Pałasz, Ewa Obuchowicz. Chronic treatment with escitalopram and venlafaxine affects the neuropeptide S pathway differently in adult Wistar rats exposed to maternal separation[J]. AIMS Neuroscience, 2022, 9(3): 395-422. doi: 10.3934/Neuroscience.2022022

    Related Papers:

    [1] Shengfang Yang, Huanhe Dong, Mingshuo Liu . New wave behaviors and stability analysis for magnetohydrodynamic flows. Networks and Heterogeneous Media, 2024, 19(2): 887-922. doi: 10.3934/nhm.2024040
    [2] Caihong Gu, Yanbin Tang . Global solution to the Cauchy problem of fractional drift diffusion system with power-law nonlinearity. Networks and Heterogeneous Media, 2023, 18(1): 109-139. doi: 10.3934/nhm.2023005
    [3] Hyeong-Ohk Bae, Hyoungsuk So, Yeonghun Youn . Interior regularity to the steady incompressible shear thinning fluids with non-Standard growth. Networks and Heterogeneous Media, 2018, 13(3): 479-491. doi: 10.3934/nhm.2018021
    [4] Maksym Berezhnyi, Evgen Khruslov . Non-standard dynamics of elastic composites. Networks and Heterogeneous Media, 2011, 6(1): 89-109. doi: 10.3934/nhm.2011.6.89
    [5] Fermín S. V. Bazán, Luciano Bedin, Mansur I. Ismailov, Leonardo S. Borges . Inverse time-dependent source problem for the heat equation with a nonlocal Wentzell-Neumann boundary condition. Networks and Heterogeneous Media, 2023, 18(4): 1747-1771. doi: 10.3934/nhm.2023076
    [6] Hantaek Bae, Rafael Granero-Belinchón, Omar Lazar . On the local and global existence of solutions to 1d transport equations with nonlocal velocity. Networks and Heterogeneous Media, 2019, 14(3): 471-487. doi: 10.3934/nhm.2019019
    [7] M. Berezhnyi, L. Berlyand, Evgen Khruslov . The homogenized model of small oscillations of complex fluids. Networks and Heterogeneous Media, 2008, 3(4): 831-862. doi: 10.3934/nhm.2008.3.831
    [8] Michiel Bertsch, Carlo Nitsch . Groundwater flow in a fissurised porous stratum. Networks and Heterogeneous Media, 2010, 5(4): 765-782. doi: 10.3934/nhm.2010.5.765
    [9] Steinar Evje, Kenneth H. Karlsen . Hyperbolic-elliptic models for well-reservoir flow. Networks and Heterogeneous Media, 2006, 1(4): 639-673. doi: 10.3934/nhm.2006.1.639
    [10] Hantaek Bae . On the local and global existence of the Hall equations with fractional Laplacian and related equations. Networks and Heterogeneous Media, 2022, 17(4): 645-663. doi: 10.3934/nhm.2022021
  • Neuropeptide S (NPS), which is a peptide that is involved in the regulation of the stress response, seems to be relevant to the mechanism of action of antidepressants that have anxiolytic properties. However, to date, there have been no reports regarding the effect of long-term treatment with escitalopram or venlafaxine on the NPS system under stress conditions.

    This study aimed to investigate the effects of the above-mentioned antidepressants on the NPS system in adult male Wistar rats that were exposed to neonatal maternal separation (MS).

    Animals were exposed to MS for 360 min. on postnatal days (PNDs) 2–15. MS causes long-lasting behavioral, endocrine and neurochemical consequences that mimic anxiety- and depression-related features. MS and non-stressed rats were given escitalopram or venlafaxine (10mg/kg) IP from PND 69 to 89. The NPS system was analyzed in the brainstem, hypothalamus, amygdala and anterior olfactory nucleus using quantitative RT-PCR and immunohistochemical methods.

    The NPS system was vulnerable to MS in the brainstem and amygdala. In the brainstem, escitalopram down-regulated NPS and NPS mRNA in the MS rats and induced a tendency to reduce the number of NPS-positive cells in the peri-locus coeruleus. In the MS rats, venlafaxine insignificantly decreased the NPSR mRNA levels in the amygdala and a number of NPSR cells in the basolateral amygdala, and increased the NPS mRNA levels in the hypothalamus.

    Our data show that the studied antidepressants affect the NPS system differently and preliminarily suggest that the NPS system might partially mediate the pharmacological effects that are induced by these drugs.



    In this paper, we investigate the existence of a least energy sign-changing solution for the following fractional p-Laplacian problem:

    (Δ)sN/su+V(x)|u|Ns2u=f(u)  in RN, (1.1)

    where s(0,1), 2<Ns:=p, (Δ)sp is the fractional p-Laplacian operator which, up to a normalizing constant, may be defined by setting

    (Δ)spu(x)=2limε0+RNBε(x)|u(x)u(y)|p2(u(x)u(y))|xy|N+psdy, xRN

    along functions uC0(RN), where Bε(x) denotes the ball of RN centered at xRN and radius ε>0. In addition, the potential VC(RN,R), the nonlinear f has exponential critical growth, and such nonlinear behavior is motivated by the Trudinger-Moser inequality (Lemma 2.2).

    Recently, the study of nonlocal problems driven by fractional operators has piqued the mathematical community's interest, both because of their intriguing theoretical structure and due to concrete applications such as obstacle problems, optimization, finance, phase transition, and so on. We refer to [18] for more details. In fact, when p=2, problem (1.1) appears in the study of standing wave solutions, i.e., solutions of the form ψ(x,t)=u(x)eiωt, to the following fractional Schrödinger equation:

    iψt=2(Δ)sψ+W(x)ψf(|ψ|) in RN×R, (1.2)

    where is the Planck constant, W:RNR is an external potential, and f is a suitable nonlinearity. Laskin [25,26] first introduced the fractional Schrödinger equation due to its fundamental importance in the study of particles on stochastic fields modeled by Lévy processes.

    After that, remarkable attention has been devoted to the study of fractional Schrödinger equations, and a lot of interesting results were obtained. For the existence, multiplicity and behavior of standing wave solutions to problem (1.2), we refer to [1,9,10,14,19,33] and the references therein.

    For general p with 2<p<Ns, problem (1.1) becomes the following fractional Laplacian problem:

    (Δ)spu+V(x)|u|p2u=f(u) in RN. (1.3)

    We emphasize that the fractional p-Laplacian is appealing because it contains two phenomena: the operator's nonlinearity and its nonlocal character. In fact, for the fractional p-Laplacian operator (Δ)sp with p2, one cannot obtain a similar equivalent definition of (Δ)sp by the harmonic extension method in [10]. For those reasons, the study of (1.3) becomes attractive. In [13], the authors obtained infinitely many sign-changing solutions of (1.3) by using the invariant sets of descent flow. Moreover, they also proved (1.3) possesses a least energy sign-changing solution via deformation Lemma and Brouwer degree. We stress that, by using a similar method, Wang and Zhou [35], Ambrosio and Isernia [3] obtained the least energy sign-changing solutions of (1.3) with p=2. For more results involving the fractional p-Laplacian, we refer to [2,17,20,21,32] and the references therein.

    Another motivation to investigate problem (1.1) comes from the fractional Schrödinger equations involving exponential critical growth. Indeed, we shall study the case where the nonlinearity f(t) has the maximum growth that allows us to treat problem (1.1) variationally in Ws,Ns(RN) (see the definition in (1.5)). If p<Ns, Sobolev embedding (Theorem 6.9 in [18]) states Ws,p(RN)Lps(RN), where ps=NpNsp, and ps is called the critical Sobolev exponent. Moreover, the same result ensures that Ws,Ns(RN)Lλ(RN) for any λ[Ns,+). However, Ws,Ns(RN) is not continuously embedded in L(RN) (for more details, we refer to [18]). On the other hand, in the case p=Ns, the maximum growth that allows us to treat problem (1.1) variationally in Sobolev space Ws,Ns(RN), which is motivated by the fractional Trudinger-Moser inequality proved by Ozawa [30] and improved by Kozono et al. [23] (see Lemma 2.2). More precisely, inspired by [23], we say that f(t) has exponential critical growth if there exists α0>0 such that

    lim|t|f(t)exp(α|t|NNs)={0,  for α>α0,+,  for α<α0.

    On the basis of this notation of critical, many authors pay their attention to investigating elliptic problems involving the fractional Laplacian operator and nonlinearities with exponential growth. When N=1,s=12, p=2 and replacing R by (a,b), problem (1.1) becomes the following fractional Laplacian equation:

    {(Δ)12u=f(u) in (a,b),u=0 in R(a,b). (1.4)

    When f is o(|t|) at the origin and behaves like exp(αt2) as |t|, by virtue of the Mountain Pass theorem, Iannizzotto and Squassina [22] proved the existence and multiplicity of solutions for (1.4). Utilizing the constrained variational methods and quantitative deformation lemma, Souza et al. [16] considered the least energy sign-changing solution of problem (1.4) involving exponential critical growth.

    For problem (1.1) with exponential critical growth nonlinearity f, we would like to mention references [8,27,34]. In [27], by applying variational methods together with a suitable Trudinger-Moser inequality for fractional space, the authors obtained at least two positive solutions of (1.1). In [8], the authors considered problem (1.1) with a Choquard logarithmic term and exponential critical growth nonlinearity f. They proved the existence of infinite many solutions via genus theory. In [34], by using Ljusternik-Schnirelmann theory, Thin obtained the existence, multiplicity and concentration of nontrivial nonnegative solutions for problem (1.1). For more recent results on fractional equations involving exponential critical growth, see [8,15,16,22,27,31,34] and the references therein. We also refer the interested readers to [11,29] for general problems with Trudinger-Moser-type behavior.

    Inspired by the works mentioned above, it is natural to ask whether problem (1.1) has sign-changing solutions when the nonlinearity f has exponential critical growth. To our knowledge, there are few works on it except [16]. Souza et al. [16] considered the case when N=1,p=2 and s=12. However, compared with [16], the situation when p>2 is quite different. In particular, the decomposition of functional I (see the definition in (1.8)) is more difficult than that in [16]. Therefore, some difficulties arise in studying the existence of a least energy sign-changing solution for problem (1.1), and this makes the study interesting.

    In order to study problem (1.1), from now on, we fix p=Ns, p=pp1=NNs and consider the following assumptions on V and f :

    (V) V(x)C(RN) and there exists V0>0 such that V(x)V0 in RN. Moreover, lim|x|V(x)=+;

    (f1) The function fC1(R) with exponential critical growth at infinity, that is, there exists a constant α0>0 such that

    lim|t||f(t)|exp(α|t|p)=0  for α>α0andlim|t||f(t)|exp(α|t|p)=  for α<α0;

    (f2) limt0|f(t)||t|p1=0;

    (f3) There exists θ>p such that

    0<θF(t)tf(t) for tR{0},

    where F(t)=t0f(s)ds; (f4)

    There are two constants q>p and γ>1 such that

    sgn(t)f(t)γ|t|q1 for tR;

    (f5) f(t)|t|p1 is an increasing function of tR{0}.

    Before stating our results, we recall some useful notations. The fractional Sobolev space Ws,p(RN), where p=Ns, is defined by

    Ws,p(RN):={uLp(RN):[u]s,p<}, (1.5)

    where [u]s,p denotes Gagliardo seminorm, that is,

    [u]s,p:=( R2N|u(x)u(y)|p|xy|N+psdxdy)1p.

    Ws,p(RN) is a uniformly convex Banach space (see [18]) with norm

    uWs,p=(upLp(RN)+[u]ps,p)1p.

    Let us consider the work space

    X:={uWs,p(RN):RNV(x)|u|pdx<+}, (1.6)

    with the norm

    uX:=([u]ps,p+RNV(x)|u|pdx)1p.

    X is a uniformly convex Banach space, and thus X is a reflexive space. By the condition (V), we have that the embedding from X into Ws,p(RN) is continuous.

    Definition 1.1. We say that uX is a weak solution of problem (1.1) if

    R2N|u(x)u(y)|p2(u(x)u(y))(φ(x)φ(y))|xy|N+psdxdy+RNV(x)|u(x)|p2u(x)φ(x)dx=RNf(u(x))φ(x)dx (1.7)

    for all φX.

    Define the energy functional I:XR associated with problem (1.1) by

    I(u)=1pR2N|u(x)u(y)|p|xy|N+psdxdy+1pRNV(x)|u|pdxRNF(u)dx. (1.8)

    By the Trudinger-Moser type inequality in [23] (see Lemma 2.2), we prove that I(u)C1(X,R), and the critical point of functional I is a weak solution of problem (1.1) (see Remark 2.2 in Section 2).

    For convenience, we consider the operator A:XX given by

    A(u),vX,X=R2N|u(x)u(y)|p2(u(x)u(y))(v(x)v(y))|xy|N+psdxdy+RNV(x)|u|p2uvdx, u,vX, (1.9)

    where X is the dual space of X. In the sequel, for simplicity, we denote ,X,X by ,. Moreover, we denote the Nehari set N associated with I by

    N={uX{0}:I(u),u=0}. (1.10)

    Clearly, N contains all the nontrivial solutions of (1.1). Define u+(x):=max{u(x),0} and u(x):=min{u(x),0}, and then the sign-changing solution of (1.1) stays on the following set:

    M={uX{0}:u±0, I(u),u+=0, I(u),u=0}. (1.11)

    Set

    c:=infuNI(u), (1.12)

    and

    m:=infuMI(u). (1.13)

    Now, we can state our main results.

    Theorem 1.1. Assume that (V) and (f1) to (f5) hold, and then problem (1.1) possesses a least energy sign-changing solution uX, provided that

    γ>γ:=[θpmqθp(α0α)p1]qpp>0,

    where α is a constant defined in Lemma 2.2,

    mq=infuMqIq(u), Mq={uX:u±0,Iq(u),u±=0},

    and

    Iq(u)=1pupX1qRN|u|qdx.

    The proof of Theorem 1.1 is based on the arguments presented in [7]. We first check that the minimum of functional I restricted on set M can be achieved. Then, by using a suitable variant of the quantitative deformation Lemma, we show that it is a critical point of I. However, due to the nonlocal term

    1pR2N|u(x)u(y)|p|xy|N+psdxdy,

    the functional I no longer satisfies the decompositions

    I(u)=I(u+)+I(u)andI(u),u±=I(u±),u±, (1.14)

    which are very useful to get sign-changing solutions of problem (1.1) (see for instance [4,5,6,7,12]). In fact, due to the fractional p-Laplacian operator (Δ)sp with s(0,1) and p2, one cannot obtain a similar equivalent definition of (Δ)sp by the harmonic extension method (see [10]). In addition, compared with [16], problem (1.1) contains nonlocal operator (Δ)sp with p>2, which brings some difficulties while studying problem (1.1). In particular, for problem (1.4), one has the following decomposition:

    J(u)=J(u+)+J(u)+R2Nu+(x)u(y)u(x)u+(y)|xy|N+2sdxdy,J(u),u+=J(u+),u++R2Nu+(x)u(y)u(x)u+(y)|xy|N+2sdxdy, (1.15)

    where J is the energy functional of (1.4). However, for the energy functional I, it is impossible to obtain a similar decomposition like (1.15) due to the nonlinearity of the operator (Δ)sp. In order to overcome this difficulty, we divide R2N into several regions (see Lemma 2.6) and decompose functional I on each region carefully. Furthermore, another difficulty arises in verifying the compactness of the minimizing sequence in X since problem (1.1) involves the exponential critical nonlinearity term. Fortunately, thanks to the Trudinger-Moser inequality in [23], we overcome this difficulty by choosing γ in assumption (f4) appropriately large to ensure the compactness of the minimizing sequence. To achieve this, a more meticulous calculation is needed in estimating m.

    On the other hand, by a similar argument in [13], we also consider the energy behavior of I(u) in the following theorem, where u is the least energy sign-changing solution obtained in Theorem 1.1.

    Theorem 1.2. Assume that (V) and (f1) to (f4) are satisfied. Then, c>0 is achieved, and

    I(u)>2c,

    where u is the least energy sign-changing solution obtained in Theorem 1.1.

    The paper is organized as follows: Section 2 contains the variational setting of problem (1.1), and it establishes a version of the Trudinger-Moser inequality for (1.1). In Section 3, we give some technical lemmas which will be crucial in proving the main result. Finally, in Section 4, we combine the minimizing arguments with a variant of the Deformation Lemma and Brouwer degree theory to prove the main result.

    Throughout this paper, we will use the following notations: Lλ(RN) denotes the usual Lebesgue space with norm ||λ; C,C1,C2, will denote different positive constants whose exact values are not essential to the exposition of arguments.

    In this section, we outline the variational framework for problem (1.1) and give some preliminary Lemmas. For convenience, we assume that V0=1 throughout this paper. Recalling the definition of fractional Sobolev space X in (1.6), we have the following compactness results.

    Lemma 2.1. Suppose that (V) holds. Then, for all λ[p,), the embedding XLλ(RN) is compact.

    Proof. Define Y=Lλ(RN) and BR={xRN:|x|<R},BcR=RN¯BR. Let X(Ω) and Y(Ω) be the spaces of functions uX,uY restricted onto ΩRN respectively. Then, it follows from Theorems 6.9, 6.10 and 7.1 in [18] that X(BR)Y(BR) is compact for any R>0. Define VR=infxBcRV(x). By (V), we deduce that VR as R. Therefore, when λ=Ns=p, we have

    BcR|u|pdx1VRBcRV(x)|u|pdx1VRupX,

    which implies

    limR+supuX{0}uLp(BcR)uX=0.

    By virtue of Theorem 7.9 in [24], we can see that XLp(RN) is compact.

    When λ>p, by the interpolation inequality, one can also obtain that XLλ(RN) is compact. This completes the proof.

    To study problems involving exponential critical growth in the fractional Sobolev space, the main tool is the following fractional Trudinger-Moser inequality, and its proof can be found in Zhang [37]. First, to make the notation concise, we set, for α>0 and tR,

    Φ(α,t)=exp(α|t|p)Skp2(α,t), (2.1)

    where Skp2(α,t)=kp2k=0αkk!|t|pk with kp=min{kN;kp}.

    Lemma 2.2. Let s(0,1) and sp = N. Then, there exists a positive constant α>0 such that

    RNΦ(α,u)dx<+, α(0,α), (2.2)

    for all uWs,p(RN) with uWs,p(RN)1.

    For Φ(α,u), we also have the following properties, which have been proved in [8,27]. For the reader's convenience, we sketch the proof here.

    Lemma 2.3. [27] Let α>0 and r>1. Then, for every β>r, there exists a constant C= C(β)>0 such that

    (exp(α|t|p)Skp2(α,t))rC(β)(exp(βα|t|p)Skp2(βα,t)).

    Proof. Noticing that

    (exp(α|t|p)Skp2(α,t))rexp(βα|t|p)Skp2(βα,t)=(j=kp1αj|t|jpj!)rj=kp1(βα)j|t|jpj!=|t|r(p1)p(j=kp1αj|t|(jp+1)pj!)r|t|(p1)pj=kp1(βα)j|t|(jp+1)pj!,

    we deduce

    limt0(exp(α|t|p)Skp2(α,t))rexp(βα|t|p)Skp2(βα,t)=0.

    On the other hand, it holds that

    lim|t|(exp(α|t|p)Sp2(α,t))rexp(βα|t|p)Sp2(βα,t)=lim|t|exp(αr|t|p)(1Sp2(α,t)(exp(α|t|))p)rexp(βα|t|p)(1Sp2(βα,t)exp(βα|t|p))=0, (2.3)

    and the lemma follows.

    Lemma 2.4. [8] Let α>0. Then, Φ(α,u)L1(RN) for all uX.

    Proof. Let uX{0} and ε>0. Since C0(RN) is dense in X, there exists ϕC0(RN) such that 0<uϕX<ε. Observe that for each kkp1,

    |u|pk2pkεpk|uϕuϕX|pk+2pk|ϕ|pk.

    Consequently,

    Φ(α,u)Φ(α2pεp,|uϕuϕX|p)+Φ(α2p,|ϕ|p).

    From Lemma 2.2, choosing ε>0 sufficiently small such that α2pεp<α, we have

    RNΦ(α2pεp,|uϕuϕX|p)dx<+.

    On the other side, since exp(α2p|ϕ|p)=+k=0αkk!2pk|ϕ|pk, there exists k0N such that +k=k0αkk!2pk|ϕ|pk<ε. This fact, combined with the fact that pk>0 for all kp1kk0, gives us

    RNΦ(α2p,|ϕ|p)dx=suppϕΦ(α2p,|ϕ|p)dx<+.

    Therefore, Φ(α,u)L1(RN) for all uX.

    Remark 2.1. From Lemmas 2.2–2.4, we deduce that Φ(α,u)lL1(RN) for all uX, α>0 and l1.

    The next lemma shows the growth behavior of the nonlinearity f.

    Lemma 2.5. Given ε>0, α>α0 and ζ>p, for all uX, it holds that

    |f(u)|ε|u|p1+C1(ε)|u|ζ1Φ(α,u),

    and

    |F(u)|εp|u|p+C2(ε)|u|ζΦ(α,u).

    Proof. We will only prove the first result. Since the second inequality is a direct consequence of the first one due to assumption (f3), we omit it here.

    In fact, by (f2), for given ε>0, there exists δ>0 such that |f(u)|ε|u|p1 for all |u|<δ. Now, as ζ>p, there exists r>0 such that ζ=p+r. Hence, once zζ1,zqk for all kkp1 and zr are increasing functions, if |u|>δ, it follows from (f1) that

    |f(u)|ε|u|p1+CεΦ(α,u)ε|u|p1|u|rΦ(α,u)δrΦ(α,δ)+Cε|u|ζ1δζ1Φ(α,u)=C1(ε)|u|ζ1Φ(α,u).

    This completes the proof.

    Remark 2.2. It follows from Lemmas 2.1–2.3 that I is well-defined on X. Moreover, IC1(X,RN), and

    I(u),v=R2N|u(x)u(y)|p2(u(x)u(y))(v(x)v(y))|xy|N+psdxdy+RNV(x)|u|p2uvdxRNf(u)vdx

    for all vX. Consequently, the critical point of I is the weak solution of problem (1.1).

    We seek the sign-changing solution of problem (1.1). As we saw in Section 1, one of the difficulties is the fact that the functional I does not possess a decomposition like (1.14). Inspired by [13,35], we have the following:

    Lemma 2.6. Let uX with u±0. Then,

    (i) I(u)>I(u+)+I(u),

    (ii) I(u),u±>I(u±),u±.

    Proof. Observe that

    I(u)=1pupXRNF(u)dx=1pA(u),uRNF(u)dx=1pA(u),u+RNF(u+)dx+1pA(u),uRNF(u)dx. (2.4)

    By density (see Di Nezza et al. Theorem 2.4 [18]), we can assume that u is continuous. Define

    (RN)+={xRN;u+(x)0} and (RN)={xRN;u(x)0}.

    Then, for uX with u±0, by a straightforward computation, one can see that

    A(u),u+=R2N|u(x)u(y)|p2(u(x)u(y))(u+(x)u+(y))|xy|N+psdxdy+RNV(x)|u+|pdx =(RN)+×(RN)+|u+(x)u+(y)|p|xy|N+psdxdy+(RN)+×(RN)|u+(x)u(y)|p1u+(x)|xy|N+psdxdy +(RN)×(RN)+|u(x)u+(y)|p1u+(y)|xy|N+psdxdy+RNV(x)|u+|pdx =A(u+),u++(RN)+×(RN)|u+(x)u(y)|p1u+(x)|u+(x)|p|xy|N+psdxdy +(RN)×(RN)+|u(x)u+(y)|p1u+(y)|u+(y)|p|xy|N+psdxdy>A(u+),u+. (2.5)

    Similarly, we also have

    A(u),u>A(u),u. (2.6)

    Taking into account (2.4)–(2.6), we deduce that I(u)>I(u+)+I(u). Analogously, one can prove (ii).

    In the last part of this section, we prove the following inequality, which will play an important role in estimating the upper bound for m:=infuMI(u).

    Lemma 2.7. For all uX with u±0 and constants σ,τ>0, it holds that

    σu++τupXσpA(u),u++τpA(u),u. (2.7)

    Furthermore, the inequality in (2.7) is an equality if and only if σ=τ.

    Proof. First, we claim the following elementary inequality holds true:

    (σa+τb)p(a+b)p1(σpa+τpb), (2.8)

    where a,b0, σ,τ>0 and p=Ns>2.

    Indeed, if a=0 or b=0, one can easily check (2.8). Thus, we can assume that a,b>0. Setting κ=aa+b and t=στ, (2.8) becomes

    (κt+(1κ))pκtp+(1κ). (2.9)

    Let us define g(t):=κtp+(1κ)(κt+(1κ))p, and then g(t)=κp[tp1(κt+(1κ))p1]. Noting that 0<κ<1, we can observe that g(1)=0, g(t)<0 for 0<t<1, and g(t)>0 for t>1. Therefore, g(t)>g(1)=0 for all t>0 and t1, which implies (2.9). Consequently, (2.8) holds true.

    Now, let us consider the inequality (2.7). By a straightforward computation, one can see from (2.8) that

    σu++τupXσpA(u),u+τpA(u),u=(RN)+×(RN)|σu+(x)τu(y)|p|u+(x)u(y)|p1(σpu+(x)τpu(y))|xy|N+psdxdy+(RN)×(RN)+|τu(x)σu+(y)|p|u(x)u+(y)|p1(τp(u(x))+σpu+(y))|xy|N+psdxdy0,

    which implies (2.7), and Lemma 2.7 follows.

    The aim of this section is to prove some technical lemmas related to the existence of a least energy nodal solution. Firstly, we collect some preliminary lemmas which will be fundamental to prove our main result.

    Lemma 3.1. Under the assumptions of Theorem 1.1, we have

    (i) For all uN such that uX, I(u);

    (ii) There exist ρ,μ>0 such that u±Xρ for all uM and uX>μ for all uN.

    Proof. (i) Since uN and (f3) holds, we see that

    I(u)=I(u)1θI(u),u(1p1θ)upX. (3.1)

    Hence, the above inequality ensures that I(u) as uX.

    (ii) We claim that there exists μ>0, such that uX>μ for all uN. By contradiction, we suppose that there exists a sequence {un}N such that unX0 in X.

    Then, it follows from Lemmas 2.1, 2.3, 2.5 and Hölder's inequality that

    unpX=RNf(un)undxεRN|un|pdx+C1(ε)RN|un|ζΦ(α,un)dxεunpX+C1(ε)(RN|un|ζrdx)1r(RNΦ(α,un)rdx)1r=εunpX+C2(ε)(RNΦ(α,un)rdx)1runζX, (3.2)

    where α>α0, ζ>p and r>1 with 1r+1r=1.

    On the other hand, since unX0, there exists N0N and ϑ>0 such that unpX<ϑ<αα0 for all n>N0. Choosing α>α0, r>1 and β>r satisfying αϑ<α and βαϑ<α, for all n>N0, we deduce from Lemmas 2.2 and 2.3 that

    RNΦ(α,un)rdx=RN(exp(α|un|p)Skp2(α,un))rdx=RN(exp(αunpX(ununX)p)Skp2(αunpX,ununX))rdxCRN(exp(βαϑ(ununX)p)Skp2(βαϑ,ununX))dxC. (3.3)

    Combining (3.3) with (3.2), and choosing ε=12 in (3.2), we can see that

    unpXCunζX, (3.4)

    where C is a constant independent of n. Obviously, (3.4) contradicts with unX0, and we have proved the claim.

    For unM, we have I(un),u±n=0. Hence, it follows from Lemma 2.6 that

    I(u±n),u±n<0,

    which implies

    u±npX<RNf(u±n)u±ndx.

    By arguments as with (3.2) and (3.3), we deduce that there exist ρ1,ρ2>0 such that u+nX>ρ1 and unX>ρ2. Select ρ=min(ρ1,ρ2), and then u±nX>ρ, and this completes the proof.

    Lemma 3.2. Under the assumptions of Theorem 1.1, for any uX{0}, there exists a unique νuR+ such that νuuN. Moreover, for any uN, we have

    I(u)=maxν[0,)I(νuu). (3.5)

    Proof. Given uX{0}, we define g(ν)=I(νu) for all ν0, i.e.,

    g(ν)=1pνpupXRNF(νu)dx.

    It follows from (f2) and (f4) that the function g(ν) possesses a global maximum point νu, and g(νu)=0, i.e.,

    νp1uupX=RNf(νuu)udx, (3.6)

    which implies νuuN. Now, we claim the uniqueness of νu. Suppose, on the contrary, there exists ˜νuνu such that ˜νuuN. Then, it holds that

    ˜νp1uupX=RNf(˜νuu)udx. (3.7)

    Without loss of generality, we may assume ˜νu>νu. Combining (3.6), (3.7) and (f5), we deduce that

    0={xRN: u(x)0}(f(˜νuu)|˜νuu|p1f(νuu)|νuu|p1)|u|p1udx>0,

    which leads to a contradiction. Thus, νu is unique. Obviously, for any uN, νu=1, and (3.5) follows. This completes our proof.

    Since we are considering the constrained minimization problem on M, in the following, we will show that the set M is nonempty.

    Lemma 3.3. If uX with u±0, then there exists a unique pair (σu,τu) of positive numbers such that

    (I(σuu++τuu),u+,I(σuu++τuu),u)=(0,0).

    Consequently, σuu++τuuM.

    Proof. Let G:(0,+)×(0,+)R2 be a continuous vector field given by

    G(σ,τ)=(I(σu++τu),σu+,I(σu++τu),τu)

    for every (σ,τ)(0,+)×(0,+). By virtue of Lemmas 2.5 and 2.6, we deduce that

    I(σu++τu),σu+I(σu+),σu+=σpu+pXRNf(σu+)σu+dxσpu+pXεσpRN|u+|pdxCεRN|σu+|ζΦ(α,σu+)dx, (3.8)

    where α>α0 and ζ>q. Choose ε=12, σ small enough such that σu+pX<αα0. Taking into account (3.8) and arguing as with (3.3) in Lemma 3.1, one can see that

    I(σu++τu),σu+12σpu+pXC1σζu+ζX, (3.9)

    and similarly

    I(σu++τu),τu12τpupXC2τζuζX. (3.10)

    Hence, it follows from (3.9) and (3.10) that there exists R1>0 small enough such that

    I(R1u++τu),R1u+>0 for all τ>0, (3.11)

    and

    I(σu++R1u),R1u>0 for all σ>0. (3.12)

    On the other hand, by (f3), there exist constants D1,D2>0 such that

    F(t)D1tθD2 for all t>0. (3.13)

    Then, we have

    I(σu++τu),σu+σp(RN)+×(RN)+|u+(x)u+(y)|p|xy|N+psdxdy+(RN)+×(RN)|σu+(x)τu(y)|p1σu+(x)|xy|N+psdxdy+(RN)×(RN)+|τu(x)σu+(y)|p1σu+(y)|xy|N+psdxdy+σpRNV(x)|u+|pdxD1σθA+|u+|θdx+D2|A+|, (3.14)

    where A+supp(u+) is a measurable set with finite and positive measure |A+|. Due to the fact that θ>p, for R2 sufficiently large, we get

    I(R2u++τu),R2u+<0 for all τ[R1,R2]. (3.15)

    Similarly, we get

    I(σu++R2u),R2u<0 for all σ[R1,R2]. (3.16)

    Hence, taking into account (3.6), (3.7), (3.15), (3.16) and thanks to the Miranda theorem [28], there exists (σu,τu)[R1,R2]×[R1,R2] such that G(σu,τu)=0, which implies σuu++τuuM.

    Now, we are in the position to prove the uniqueness of the pair (σu,τu). First, we assume that u=u++uM and (σu,τu)(0,+)×(0,) is another pair such that σuu++τuuM. In this case, we just need to prove that (σu,τu)=(1,1). Notice that

    A(u),u+=RNf(u+)u+dx, A(u),u=RNf(u)udx, (3.17)

    and

    A(σuu++τuu),σuu+=RNf(σuu+)σuu+dx, A(σuu++τuu),τuu=RNf(τuu)τuudx. (3.18)

    Without loss of generality, we may assume σuτu. Then, by a direct computation, one has

    A(σuu++τuu),σuu+=(RN)+×(RN)+|σuu+(x)σuu+(y)|p|xy|N+psdxdy+(RN)+×(RN)|σuu+(x)τuu(y)|p1σuu+(x)|xy|N+psdxdy+(RN)×(RN)+|τuu(x)σuu+(y)|p1σuu+(y)|xy|N+psdxdyA(σuu++σuu),σuu+=σpuA(u),u+, (3.19)

    which together with (3.18) implies

    σpuA(u),u+RNf(σuu+)σuu+dx. (3.20)

    Combining (3.20) with (3.17), we deduce that

    {xRN:u+(x)0}(f(σuu+)(σuu+)p1f(u+)(u+)p1)(u+)pdx0.

    Hence, by (f5) and since u+0, we obtain σu1. Moreover, using similar arguments as in (3.19), we can deduce that

    A(σuu++τuu),τuuA(τuu++τuu),τuu. (3.21)

    Therefore, it follows from (3.17), (3.18) and (3.21) that

    {xRN: u(x)0}(f(τuu)(τuu)p1f(u)(u)p1)(u)pdx0,

    which together with (f5) implies τu1. Thus, we conclude the proof of the uniqueness of the pair (1,1).

    For the general case, we suppose that u does not necessarily belong to M. Let (σu,τu), (σu,τu)(0,+)×(0,). We define v=v++v with v+=σuu+ and v=τuu. Therefore, we have vM and σuσuv++τuτuvM, which implies (σu,τu)=(σu,τu), and this completes the proof.

    The following two lemmas will be useful in proving Theorem 1.1.

    Lemma 3.4. Under the assumptions of Theorem 1.1, and let uX with u±0 such that I(u),u±0. Then, the unique pair of positive numbers obtained in Lemma 3.3 satisfies 0<σu,τu1.

    Proof. Here we will only prove 0<σu1. The proof of 0<τu1 is analogous, and we omit it here. Since I(u),u+0, it holds that

    A(u),u+RNf(u+)u+dx. (3.22)

    Without loss of generality, we can assume that σuτu>0, and σuu++τuuM. Therefore, utilizing a similar argument as in (3.19), we deduce that

    σpuA(u),u+=A(σuu++σuu),σuu+A(σuu++τuu),σuu+=RNf(σuu+)σuu+dx. (3.23)

    Taking into account (3.22) and (3.23), we obtain

    RN(f(σuu+)(σuu+)p1f(u+)(u+)p1)(u+)pdx0,

    which together with assumption (f5) and the fact u+0 shows that σu1. Hence, we finish the proof.

    Lemma 3.5. Under the assumptions of Theorem 1.1, let uX with u±0 and (σu,τu) be the unique pair of positive numbers obtained in Lemma 3.3. Then, (σu,τu) is the unique maximum point of the function hu:[0,+)×[0,+)R given by

    hu(σ,τ):=I(σu++τu).

    Proof. In the demonstration of Lemma 3.3, we saw that (σu,τu) is the unique critical point of hu in (0,+)×(0,+). In addition, by the definition of hu and (3.13), we have

    hu(σ,τ)=I(σu++τu)1pσu++τupXD1σθA+|u+|θdxD1τθA|τu|θdx+D2(|A+|+|A|),

    where A+supp(u+) and Asupp(u) are measurable sets with finite and positive measures |A+| and |A|. Since θ>p, we conclude that hu(σ,τ) as |(σ,τ)|. In particular, one can easily check that there exists R>0 such that hu(a,b)<hu(σu,τu) for all (a,b) (0,)×(0,)¯BR(0), where ¯BR(0) is a closure of the ball of radius R in R2.

    To end the proof, we just need to verify that the maximum of hu does not occur in the boundary of [0,+)×[0,+). Suppose, by contradiction, that (0,b) is a maximum point of hu. Then, for a>0 small enough, one can see from (3.9) that hu(a,0)=I(au+)>0. Hence, it follows from Lemma 2.6 that

    hu(a,b)=I(au++bu)>I(au+)+I(bu)>hu(0,b),

    for a>0 small enough. However, this contradicts with the assumption that (0,b) is a maximum point of hu. The case (a,0) is similar, and we complete the proof.

    Since Lemma 3.3 shows M is nonempty, and Lemma 3.1 implies that I(u)>0 for all uM, I is bounded below in M, which means that m:=infuMI(u) is well-defined. Now, we shall prove an upper bound for m to recover the compactness, which urges us to prove that m can be achieved.

    Lemma 3.6. Under the assumptions of Theorem 1.1 and that θ is the constant given by (f3),

    0<m<θpθp(αα0)p1. (3.24)

    Proof. Due to MN, we have mc:=infuNI(u). Moreover, for all uN, by Lemma 3.1 it holds that

    I(u)(1p1θ)upXθpθpμp>0. (3.25)

    On the other hand, by the similar procedure used in [13], there exists wMq with w±0, such that Iq(w)=mq and Iq(w),w±=0. Therefore, it holds that

    1pwpX1q|w|qq=mq  and  A(w),w±=|w±|qq. (3.26)

    In addition, by virtue of Lemma 3.3, there exist σ,τ>0 such that σw++τwM. Therefore, it holds that

    mI(σw++τw)=1pσw++τwpXRNF(σw++τw)dx,

    which together with (f4) implies that

    m1pσw++τwpXγqσq|w+|qqγqτq|w|qq.

    Now, from (3.26) and thanks to Lemma 2.7, we conclude that

    m1pσpA(w),w++1pτpA(w),wγqσq|w+|qqγqτq|w|qq+1p(σw++τwpXσpA(w),w+τpA(w),w)(1pσpγqσq)|w+|qq+(1pτpγqτq)|w|qqmaxξ0(1pξpγqξq)|w|qq=(1p1q)γppq|w|qq=γppqmq.

    Therefore, by the definition of γ in Theorem 1.1, we obtain (3.24).

    Lemma 3.7. Under the assumptions of Theorem 1.1, let {un}M be a minimizing sequence for m, and then

    RNf(u±n)u±ndxRNf(u±)u±dx as n, (3.27)

    and

    RNF(u±n)dxRNF(u±)dx as n (3.28)

    hold for some uX.

    Proof. We will only prove the first result, since the second limit is a direct consequence of the first one. Since {un}M is a minimizing sequence for m, I(un)m, and it follows from (3.25) that

    unpXθpθpI(un), (3.29)

    which implies {un} is bounded in X. Then, by virtue of Lemma 2.1, up to a subsequence, there exists uX such that

    unu in X,unu in Lλ(RN) for λ[p,+),unu  a.e. in RN. (3.30)

    Hence,

    u±nu± in X,u±nu± in Lλ(RN) for λ[p,+),u±nu±  a.e. in RN. (3.31)

    Moreover, utilizing (3.29) again, we deduce that there exist n0N and ϑ>0 such that unpX<ϑ<αα0 for n>n0. Choose α>α0, r>1 and close to 1, and β>r satisfying αϑ<α and βαϑ<α, and then for all n>n0, it follows from Lemmas 2.2 and (3) that

    RNΦ(α,un)rdx=RN(exp(α|un|p)Skp2(α,un))rdx=RN(exp(αunpX(ununX)p)Skp2(αunpX,ununX))rdxCRN(exp(βαϑ(ununX)p)Skp2(βαϑ,ununX))C, (3.32)

    where C is a constant independent of n. Thus, by virtue of Lemma 2.5 and Hölder's inequality, for every Lebesgue measurable set ARN and n>n0, it holds that

    |Af(un)undx|C1A|un|pdx+C2A|un|ζΦ(α,un)dxC1A|un|pdx+C2(A|un|ζrdx)1r(AΦ(α,un)rdx)1r=C1A|un|pdx+C2C1r(A|un|ζrdx)1r. (3.33)

    Due to (3.33) and the fact that u±nu± in Lp(RN) and Lζr(RN), we conclude that for any ε>0 and n>n0, there exists δ>0 such that for every Lebesgue measurable set ARN with meas(A)δ, it holds that

    |Af(u±n)u±ndx|<ε. (3.34)

    Similarly, for any ε>0 and n>n0, there exists R>0 such that

    | RNBR(0)f(u±n)u±ndx|<ε. (3.35)

    Therefore, by (3.31), (3.34), (3.35) and thanks to Vitali's convergence theorem, one can prove

    RNf(u±n)u±ndxRNf(u±)u±dx as n. (3.36)

    Thus, we finish the proof.

    In this section, we will prove Theorems 1.1 and 1.2. To this end, we consider the minimization problem

    m:=infuMI(u).

    Firstly, let us start with the existence of a minimizer uM of I.

    Lemma 4.1. Under the assumptions of Theorem 1.1, the infimum m is achieved.

    Proof. By using Lemma 3.1, we know that there exists a minimizing sequence {un}nM bounded in X, such that

    I(un)m  as n. (4.1)

    Without loss of generality, we may assume up to a subsequence that there exists u such that

    u±n(u)± in X,u±n(u)± in Lλ(RN) for all λ[p,+),u±n(u)± a.e. in RN.

    Then, by Lemmas 2.6, 3.1 and 3.7, we conclude that

    ρplim infnu±npXlim infnA(un),u±n=lim infnRNf(u±n)u±ndx=RNf((u)±)(u)±dx,

    which implies (u)±0, and consequently u=(u)++(u) is sign-changing. Hence, by Lemma 3.3, there exist σ,τ>0 such that

    I(σ(u)++τ(u)),(u)+=0,I(σ(u)++τ(u)),(u)=0. (4.2)

    Now, we claim that σ=τ=1. Indeed, since unM, I(un),u±n=0, i.e.,

    u+npX+(RN)+n×(RN)n(|u+n(x)un(y)|p1u+n(x)|xy|N+ps|u+n(x)|p|xy|N+ps)dxdy+(RN)n×(RN)+n(|un(x)u+n(y)|p1u+n(y)|xy|N+ps|u+n(y)|p|xy|N+ps)dxdy=RNf(u+n)u+ndx, (4.3)

    and

    unpX+(RN)n×(RN)+n(|un(x)u+n(y)|p1(un(x))|xy|N+ps|un(x)|p|xy|N+ps)dxdy+(RN)+n×(RN)n(|u+n(x)un(y)|p1(un(y))|xy|N+ps|un(y)|p|xy|N+ps)dxdy=RNf(un)undx, (4.4)

    where (RN)+n:={xRN:un(x)0} and (RN)n:={xRN:un(x)0}. Notice the functional upX is weakly lower semicontinuous on X, and we see that

    (u)±pXlim infnu±npX. (4.5)

    Moreover, it follows from Lemma 3.7 that

    RNf(u±n)u±ndxRNf((u)±)(u)±dx as n. (4.6)

    Taking into account (4.3)–(4.6) and thanks to Fatou's lemma, we deduce that

    I(u),(u)+0 and I(u),(u)0, (4.7)

    which together with Lemma 3.4 implies that 0<σ,τ1. In the following, we will show that σ=τ=1, and I(u)=m. In fact, by (4.2), (f5), Fatou's lemma and the definition of M, one has

    mI(σ(u)++τ(u))=I(σ(u)++τ(u))1pI(σ(u)++τ(u)),(σ(u)++τ(u))=RN[1pf(σ(u)+)σ(u)+F(σ(u)+)]dx+RN[1pf(τ(u))τ(u)F(τ(u))]dxRN[1pf((u)+)(u)+F((u)+)]dx+RN[1pf((u))(u)F((u))]dxlim infn[I(un)1pI(un),un]=limnI(un)=m. (4.8)

    Let us observe that by the above calculation we can infer that σ=τ=1. Thus, uM, and I(u)=m.

    Now we are ready to prove Theorem 1.1. The proof is based on the quantitative deformation lemma and Brouwer degree theory. For more details, we refer to the arguments used in [7].

    Proof of Theorem 1.1. We assume by contradiction that I(u)0. Then, there exist δ,κ>0 such that

    |I(v)|κ, for all vuX3δ.

    Define D:=[1δ1,1+δ1]×[1δ1,1+δ1] and a map ξ:DX by

    ξ(σ,τ):=σ(u)++τ(u),

    where δ1(0,12) small enough such that ξ(σ,τ)uX3δ for all (σ,τ)ˉD. Thus, by virtue of Lemma 4.1, we can see that

    I(ξ(1,1))=m, I(ξ(σ,τ))<m for all (σ,τ)D{(1,1)}.

    Therefore,

    β:=max(σ,τ)DI(ξ(σ,τ))<m.

    By using [36,Theorem 2.3] with

    Sδ:={vX:vuXδ}

    and c:=m. By choosing ε:=min{mβ4,κδ8}, we deduce that there exists a deformation ηC([0,1]×X,X) such that:

    (i) η(t,v)=v if vI1([m2ε,m+2ε]); (ii) I(η(1,v))mε for each vX with vuXδ and I(v)m+ε; (iii) I(η(1,v))I(v) for all uX.

    By (ii) and (iii) we conclude that

    max(σ,τ)¯DI(η(1,ξ(σ,τ)))<m. (4.9)

    Therefore, to complete the proof of this Lemma, it suffices to prove that

    η(1,ξ(¯D))M. (4.10)

    Indeed, if (4.10) holds true, then by the definition of m and (4.9), we get a contradiction.

    In the following, we will prove (4.10). To this end, let us define Ψu:[0,+)×[0,+)R2 by

    Ψu(σ,τ):=(Ψu1(σ,τ),Ψu2(σ,τ))=(I(σ(u)++τ(u)),(u)+,I(σ(u)++τ(u)),(u)).

    Furthermore, for (σ,τ)¯D, we define

    ˜Ψ(σ,τ):=(1σI(η(1,ξ(σ,τ))),η+(1,ξ(σ,τ)),1τI(η(1,ξ(σ,τ))),η(1,ξ(σ,τ))).

    Since η(1,ξ(σ,τ))=ξ(σ,τ) on D, by the Brouwer degree theory (see Theorem D.9 [36]), we have

    deg(˜Ψ,D,0)=deg(Ψu,D,0). (4.11)

    Now, we assert that deg(Ψu,D,0)=1. If this assertion holds true, then ˜Ψ(σ0,τ0)=0 for some (σ0,τ0)D. Thus, there exists u0:=η(1,ξ(σ0,τ0))M and (4.10) follows.

    In fact, let us first define

    Ap:=R2N|u(x)u(y)|p2|(u)+(x)(u)+(y)|2|xy|N+psdxdy+RNV(x)|(u)+|pdx,Bp:=R2N|u(x)u(y)|p2|(u)(x)(u)(y)|2|xy|N+psdxdy+RNV(x)|(u)|pdx,Cp:=R2N|u(x)u(y)|p2((u)(x)(u)(y))((u)+(x)(u)+(y))|xy|N+psdxdy,Dp:=R2N|u(x)u(y)|p2((u)+(x)(u)+(y))((u)(x)(u)(y))|xy|N+psdxdy,a1:=RNf((u)+)|(u)+|2dx, a2:=RNf((u)+)(u)+dx,b1:=RNf((u))|(u)|2dx, b2:=RNf((u))(u)dx.

    Clearly, Cp=Dp>0, Ap,Bp>0. Notice that uM, and we can see that

    Ap+Cp=a2,Bp+Dp=b2. (4.12)

    Moreover, (f5) guarantees

    a1>(p1)a2,b1>(p1)b2. (4.13)

    Then, by a direct computation, we have

    Ψu1σ(1,1)=(p1)Apa1<0, (4.14)

    and

    Ψu2τ(1,1)=(p1)Bpb1<0. (4.15)

    In addition,

    Ψu1τ(1,1)=Ψu2σ(1,1)=(p1)Cp=(p1)Dp. (4.16)

    Taking advantage of (4.12)–(4.16), we deduce that

    det(Ψu)(1,1)=[(p1)Apa1][(p1)Bpb1](p1)2CpDp>[(p1)a2(p1)Ap][(p1)b2(p1)Bp](p1)2CpDp=(p1)2CpDp(p1)2CpDp=0. (4.17)

    Notice that uM, and thanks to Lemmas 3.3 and 3.5, it holds that

    deg(Ψu,D,0)=sgn(det(Ψu)(1,1))=1,

    which together with (4.11) implies deg(Ψu,D,0)=1. This completes our proof.

    Lemma 4.2. For any vM, there exist ˜σv,˜τv(0,1) such that ˜σvv+,˜τvvN.

    Proof. We just prove ˜σv(0,1). The other case can be obtained by similar arguments. Since vM, i.e., I(v),v+=0, by Lemma 2.6, we obtain

    v+pX<RNf(v+)v+dx. (4.18)

    On the other hand, by Lemma 3.2, there exists ˜σv>0 such that ˜σvv+N, which implies that

    ˜σpvv+pX=RNf(˜σvv+)˜σvv+dx. (4.19)

    Taking into account (4.9) and (4.10), we deduce that

    RN[f(v+)(v+)p1f(˜σvv+)(˜σvv+)p1](˜σvv+)pdx>0.

    Thus, it follows from (f4) that ˜σv<1.

    Proof of Theorem 1.2. Using a similar idea from the proof of Lemma 4.1, we find ˉuN such that I(ˉu)=c>0, where c:=infuNI(u). Furthermore, utilizing the same steps of the proof of Theorem 1.1, we show that I(ˉu)=0. Thus, ˉu is a ground state solution of problem (1.1). Hence, to complete the proof of Theorem 1.2, we need to study the energy behavior of I(u), where u is the sign-changing solution of (1.1) obtained in Theorem 1.1.

    In fact, by Lemma 4.2, there exist 0<˜σu,˜τu<1 such that ˜σu(u)+,˜τu(u)N. Therefore, we deduce from (f5) and Lemma 3.2 that

    m=I(u)=I(u)1pI(u),u=RN(1pf(u)uF(u))dx>RN(1pf(˜σu(u)+)˜σu(u)+F(˜σu(u)+))dx+RN(1pf(˜τu(u))˜τu(u)F(˜τu(u)))dx=I(˜σu(u)+)1pI(˜σu(u)+),˜σu(u)++I(˜τu(u))1pI(˜τu(u)),˜τu(u)=I(˜σu(u)+)+I(˜τu(u))2c,

    which completes the proof of Theorem 1.2.

    This manuscript has employed the variational method to study the fractional p-Laplacian equation involving Trudinger-Moser nonlinearity. By using the constrained variational methods, quantitative Deformation Lemma and Brouwer degree theory, we prove the existence of least energy sign-changing solutions for the problem.

    K. Cheng was supported by the Jiangxi Provincial Natural Science Foundation (20202BABL211005), W. Huang was supported by the Jiangxi Provincial Natural Science Foundation (20202BABL211004), and L. Wang was supported by the National Natural Science Foundation of China (No. 12161038) and the Science and Technology project of Jiangxi provincial Department of Education (Grant No. GJJ212204).

    The authors declare that there is no conflict of interest.


    Acknowledgments



    We thank Prof. Ryszard Wiaderkiewicz, Head of Department of Histology and Embryology at the Medical University of Silesia, for facilitating the histochemical analysis. The assistance of technical workers is gratefully acknowledged.
    The authors would also like to thank ADAMED (Poland) for supplying the antidepressants used in the study.

    Conflict of interest



    The authors do not declare any conflict of interest.

    Author contributions



    Conceptualization, EO and MG; investigation, MG, MZ, MP-S; technical support, AP; statistical analysis, MG; data curation, MG; writing—original draft preparation, MG; writing—review and editing, EO. All authors have read and agreed to the publishing of this version of the manuscript.

    Funding source



    This work was supported by a doctoral grant (KNW-2-046/D/7/N) and a statutory grant (KNW-1-094/N/8/O) from the Medical University of Silesia, Katowice, Poland.

    [1] Kormos V, Gaszner B (2013) Role of neuropeptides in anxiety, stress, and depression: from animals to humans. Neuropeptides 47: 401-419. https://doi.org/10.1016/j.npep.2013.10.014
    [2] Yamazoe M, Shiosaka S, Emson PC, et al. (1985) Distribution of neuropeptide Y in the lower brainstem: an immunohistochemical analysis. Brain Res 335: 109-120. https://doi.org/10.1016/0006-8993(85)90281-1
    [3] Douglas FL, Palkovits M, Brownstein MJ (1982) Regional distribution of substance P-like immunoreactivity in the lower brainstem of the rat. Brain Res 245: 376-378. https://doi.org/10.1016/0006-8993(82)90821-6
    [4] Spirovski D, Li Q, Pilowsky PM (2012) Brainstem galanin-synthesizing neurons are differentially activated by chemoreceptor stimuli and represent a subpopulation of respiratory neurons. J Comp Neurol 520: 154-173. https://doi.org/10.1002/cne.22723
    [5] Liu C, Lovenberg TW (2008) Relaxin-3, INSL5, and their receptors. Orphan G Protein-Coupled Receptors and Novel Neuropeptides, 46. Berlin, Heidelberg: Springer 213-237. https://doi.org/10.1007/400_2007_055
    [6] Palasz A, Rojczyk E, Golyszny M, et al. (2016) Long-term treatment with haloperidol affects neuropeptide S and NPSR mRNA levels in the rat brain. Acta Neuropsychiatr 28: 110-116. https://doi.org/10.1017/neu.2015.56
    [7] Pałasz A, Żarczyński P, Bogus K, et al. (2021) Modulatory effect of olanzapine on SMIM20/phoenixin, NPQ/spexin and NUCB2/nesfatin-1 gene expressions in the rat brainstem. Pharmacol Rep 73: 1188-1194. https://doi.org/10.1007/s43440-021-00267-7
    [8] Kumsta R, Chen FS, Pape HC, et al. (2013) Neuropeptide S receptor gene is associated with cortisol responses to social stress in humans. Biol Psychol 93: 304-307. https://doi.org/10.1016/j.biopsycho.2013.02.018
    [9] Smith KL, Patterson M, Dhillo WS, et al. (2006) Neuropeptide S stimulates the hypothalamo-pituitary-adrenal axis and inhibits food intake. Endocrinology 147: 3510-3518. https://doi.org/10.1210/en.2005-1280
    [10] Pape HC, Jüngling K, Seidenbecher T, et al. (2010) Neuropeptide S: a transmitter system in the brain regulating fear and anxiety. Neuropharmacology 58: 29-34. https://doi.org/10.1016/j.neuropharm.2009.06.001
    [11] Xu YL, Gall CM, Jackson VR, et al. (2007) Distribution of neuropeptide S receptor mRNA and neurochemical characteristics of neuropeptide S-expressing neurons in the rat brain. J Comp Neurol 500: 84-102. https://doi.org/10.1002/cne.21159
    [12] Leonard SK, Ring RH (2011) Immunohistochemical localization of the neuropeptide S receptor in the rat central nervous system. Neuroscience 172: 153-163. https://doi.org/10.1016/j.neuroscience.2010.10.020
    [13] Nauta WJ (1958) Hippocampal projections and related neural pathways to the midbrainin the cat. Brain 81: 319-340. https://link.springer.com/chapter/10.1007/978-1-4684-7920-1_9
    [14] Nauta WJ, Domesick VB (1982) Neural associations of the limbic system. Dordrecht: Springer 175-206. https://doi.org/10.1007/978-94-011-6302-6_10
    [15] Soudryl Y, Lemogne C, Malinvaud D, et al. (2011) Olfactory system and emotion: common substrates. Eur Ann Otorhinolaryngol Head Neck Dis 128: 18-23. https://doi.org/10.1016/j.anorl.2010.09.007
    [16] Xu YL, Reinscheid RK, Huitron-Resendiz S, et al. (2004) Neuropeptide S: a neuropeptide promoting arousal and anxiolytic-like effects. Neuron 43: 487-497. https://doi.org/10.1016/j.neuron.2004.08.005
    [17] Clark SD, Duangdao DM, Schulz S, et al. (2011) Anatomical characterization of the neuropeptide S system in the mouse brain by in situ hybridization and immunohistochemistry. J Comp Neurol 519: 1867-1893. https://doi.org/10.1002/cne.22606
    [18] Si W, Aluisio L, Okamura N, et al. (2010) Neuropeptide S stimulates dopaminergic neurotransmission in the medial prefrontal cortex. J Neurochem 115: 475-482. https://doi.org/10.1111/j.1471-4159.2010.06947.x
    [19] Mochizuki T, Kim J, Sasaki K (2010) Microinjection of neuropeptide S into the rat ventral tegmental area induces hyperactivity and increases extracellular levels of dopamine metabolites in the nucleus accumbens shell. Peptides 31: 926-931. https://doi.org/10.1016/j.peptides.2010.02.006
    [20] Raiteri L, Luccini E, Romei C, et al. (2009) Neuropeptide S selectively inhibits the release of 5-HT and noradrenaline from mouse frontal cortex nerve endings. Br J Pharmacol 157: 474-481. https://doi.org/10.1111/j.1476-5381.2009.00163.x
    [21] Pałasz A, Rojczyk E (2015) Neuroleptics affect neuropeptide S and NPSR mRNA levels in the rat brain. J Mol Neurosci 57: 352-357. https://doi.org/10.1007/s12031-015-0625-3
    [22] Gołyszny M, Obuchowicz E (2019) Are neuropeptides relevant for the mechanism of action of SSRIs?. Neuropeptides 75: 1-17. https://doi.org/10.1016/j.npep.2019.02.002
    [23] Laux G (2021) Serotonin Reuptake Inhibitors: Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, and Sertraline. NeuroPsychopharmacotherapy. Cham.: Springer 1-13. https://doi.org/10.1007/978-3-319-56015-1_413-1
    [24] Feng RF, Ma R, Wang P, et al. (2022) Efficacy of escitalopram for poststroke depression: a systematic review and meta-analysis. Sci Rep 12: 1-10. https://doi.org/10.1038/s41598-022-05560-w
    [25] Zhong H, Haddjeri N, Sánchez C (2012) Escitalopram, an antidepressant with an allosteric effect at the serotonin transporter—a review of current understanding of its mechanism of action. Psychopharmacology 219: 1-13. https://doi.org/10.1007/s00213-011-2463-5
    [26] Pałasz A, Suszka-Świtek A, Filipczyk Ł, et al. (2016) Escitalopram affects spexin expression in the rat hypothalamus, hippocampus and striatum. Pharmacol Rep 68: 1326-1331. https://doi.org/10.1016/j.pharep.2016.09.002
    [27] Pałasz A, Piwowarczyk-Nowak A, Suszka-Świtek A, et al. (2020) Escitalopram as a modulator of proopiomelanocortin, kisspeptin, Kiss1R and MCHR1 gene expressions in the male rat brain. Mol Biol Rep 47: 8273-8278. https://doi.org/10.1007/s11033-020-05806-8
    [28] Gołyszny M, Zieliński M, Paul-Samojedny M, et al. (2022) Escitalopram alters the hypothalamic OX system but does not affect its up-regulation induced by early-life stress in adult rats. Neurosci Res . Ahead of print. https//doi.org/10.1016/j.neures.2022.02.005
    [29] Stahl SM, Morrissette DA, Faedda G, et al. (2017) Guidelines for the recognition and management of mixed depression. CNS Spectrums 22: 203-219. https://doi.org/10.1017/S1092852917000165
    [30] Roseboom PH, Kalin NH (2000) Neuropharmacology of venlafaxine. DepressAnxiety 12: 20-29. https://doi.org/10.1002/1520-6394(2000)12:1+<20::AID-DA3>3.0.CO;2-M
    [31] Stout SC, Owens MJ, Nemeroff CB (2002) Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. J Pharmacol Exp Ther 300: 1085-1092. https://doi.org/10.1124/jpet.300.3.1085
    [32] Petschner P, Juhasz G, Tamasi V, et al. (2016) Chronic venlafaxine treatment fails to alter the levels of galanin system transcripts in normal rats. Neuropeptides 57: 65-70. https://doi.org/10.1016/j.npep.2016.01.010
    [33] Poretti MB, Sawant RS, Rask-Andersen M, et al. (2016) Reduced vasopressin receptors activation mediates the anti-depressant effects of fluoxetine and venlafaxine in bulbectomy model of depression. Psychopharmacology 233: 1077-1086. https://doi.org/10.1007/s00213-015-4187-4
    [34] LeMoult J, Humphreys KL, Tracy A, et al. (2020) Meta-analysis: exposure to early life stress and risk for depression in childhood and adolescence. J Am Acad Child Adolesc Psychiatry 59: 842-855. https://doi.org/10.1016/j.jaac.2019.10.011
    [35] Pervanidou P, Makris G, Chrousos G, et al. (2020) Early life stress and pediatric posttraumatic stress disorder. Brain Sci 10: 169. https://doi.org/10.3390/brainsci10030169
    [36] Arborelius L, Hawks BW, Owens MJ, et al. (2004) Increased responsiveness of presumed 5-HT cells to citalopram in adult rats subjected to prolonged maternal separation relative to brief separation. Psychopharmacology 176: 248-255. https://doi.org/10.1007/s00213-004-1883-x
    [37] Lippmann M, Bress A, Nemeroff CB, et al. (2007) Long-term behavioural and molecular alterations associated with maternal separation in rats. Eur J Neurosci 25: 3091-3098. https://doi.org/10.1111/j.1460-9568.2007.05522.x
    [38] Roque S, Mesquita AR, Palha JA, et al. (2014) The behavioral and immunological impact of maternal separation: a matter of timing. Front BehavNeurosci 8: 192. https://doi.org/10.3389/fnbeh.2014.00192
    [39] Bonapersona V, Joels M, Sarabdjitsingh RA (2018) Effects of early life stress on biochemical indicators of the dopaminergic system: A 3 level meta-analysis of rodent studies. NeurosciBiobehav Rev 95: 1-16. https://doi.org/10.1016/j.neubiorev.2018.09.003
    [40] Bravo JA, Dinan TG, Cryan JF (2014) Early-life stress induces persistent alterations in 5-HT1A receptor and serotonin transporter mRNA expression in the adult rat brain. Front Mol Neurosci 7: 1-9. https://doi.org/10.3389/fnmol.2014.00024
    [41] González-Pardo H, Arias JL, Gómez-Lázaro E, et al. (2020) Sex-specific effects of early life stress on brain mitochondrial function, monoamine levels and neuroinflammation. Brain Sci 10: 447. https://doi.org/10.3390/brainsci10070447
    [42] Nishi M (2020) Effects of early-life stress on the brain and behaviors: implications of early maternal separation in rodents. Int J Mol Sci 21: 7212. https://doi.org/10.3390/ijms21197212
    [43] Miragaia AS, de Oliveira Wertheimer GS, Consoli AC, et al. (2018) Maternal deprivation increases anxiety-and depressive-like behaviors in an age-dependent fashion and reduces neuropeptide Y expression in the amygdala and hippocampus of male and female young adult rats. Front BehavNeurosci 12: 159. https://doi.org/10.3389/fnbeh.2018.00159
    [44] Feng P, Vurbic D, Wu Z, et al. (2007) Brain orexins and wake regulation in rats exposed to maternal deprivation. Brain Res 1154: 163-172. https://doi.org/10.1016/j.brainres.2007.03.077
    [45] Marco EM, Llorente R, López-Gallardo M, et al. (2015) The maternal deprivation animal model revisited. NeurosciBiobehav Rev 51: 151-163. https://doi.org/10.1016/j.neubiorev.2015.01.015
    [46] Bülbül M, Sinen O (2022) The influence of early-life and adulthood stressors on brain neuropeptide-S system. Neuropeptides 92: 102223. https://doi.org/10.1016/j.npep.2021.102223
    [47] Harrison EL, Baune BT (2014) Modulation of early stress-induced neurobiological changes: a review of behavioural and pharmacological interventions in animal models. Transl Psychiatry 4: 390. https://doi.org/10.1038/tp.2014.31
    [48] Botticelli L, Micioni Di Bonaventura E, Ubaldi M, et al. (2021) The Neural Network of Neuropeptide S (NPS): Implications in food intake and gastrointestinal functions. Pharmaceuticals 14: 293. https://doi.org/10.3390/ph14040293
    [49] Gur E, Dremencov E, Lerer B, et al. (1999) Venlafaxine: acute and chronic effects on 5-hydroxytryptamine levels in rat brain in vivo. Eur J Pharmacol 372: 17-24. https://doi.org/10.1016/S0014-2999(99)00164-8
    [50] Dazzi L, Vignone V, Seu E, et al. (2002) Inhibition by venlafaxine of the increase in norepinephrine output in rat prefrontal cortex elicited by acute stress or by the anxiogenic drug FG 7142. J Psychopharmacol 16: 125-131. https://doi.org/10.1177/026988110201600202
    [51] Flandreau EI, Bourke CH, Ressler KJ, et al. (2013) Escitalopram alters gene expression and HPA axis reactivity in rats following chronic overexpression of corticotropin-releasing factor from the central amygdala. Psychoneuroendocrinology 38: 1349-1361. https://doi.org/10.1016/j.psyneuen.2012.11.020
    [52] Mesquita AR, Pêgo JM, Summavielle T, et al. (2007) Neurodevelopment milestone abnormalities in rats exposed to stress in early life. Neuroscience 147: 1022-1033. https://doi.org/10.1016/j.neuroscience.2007.04.007
    [53] Levine S, Huchton DM, Wiener SG, et al. (1991) Time course of the effect of maternal deprivation on the hypothalamic-pituitary-adrenal axis in the infant rat. Dev Psychobiol 24: 547-558. https://doi.org/10.1002/dev.420240803
    [54] Suchecki D, Mozaffarian D, Gross G, et al. (1993) Effects of maternal deprivation on the ACTH stress response in the infant rat. Neuroendocrinology 57: 204-212. https://doi.org/10.1159/000126361
    [55] Lehmann J, Pryce CR, Bettschen D, et al. (1999) The maternal separation paradigm and adult emotionality and cognition in male and female Wistar rats. PharmacolBiochemBehav 64: 705-715. https://doi.org/10.1016/S0091-3057(99)00150-1
    [56] Marcondes FK, Miguel KJ, Melo LL, et al. (2001) Estrous cycle influences the response of female rats in the elevated plus-maze test. PhysiolBehav 74: 435-440. https://doi.org/10.1016/S0031-9384(01)00593-5
    [57] Dimatelis JJ, Vermeulen IM, Bugarith K, et al. (2016) Female rats are resistant to developing the depressive phenotype induced by maternal separation stress. Metab Brain Dis 31: 109-119. https://doi.org/10.1007/s11011-015-9723-8
    [58] Paxinos G, Watson C (2006) The rat brain in stereotaxic coordinates: hard cover edition.Elsevier. https://books.google.pl/books?hl=pl&lr=&id=0prYfdDbh58C&oi=fnd&pg=PP1&dq=Paxinos+G,+Watson+C.+The+rat+brain+in+stereotaxic+coordinates:+hard+cover+edition.+Elsevier.+2006.&ots=-9hrEYXGxj&sig=NOP1J-I81ZXmlNrTabF7eFjhEVM&redir_esc=y#v=onepage&q=Paxinos%20G%2C%20Watson%20C.%20The%20rat%20brain%20in%20stereotaxic%20coordinates%3A%20hard%20cover%20edition.%20Elsevier.%202006.&f=false
    [59] Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159. https://doi.org/10.1016/0003-2697(87)90021-2
    [60] Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2− ΔΔCT method. Methods 25: 402-408. https://doi.org/10.1006/meth.2001.1262
    [61] Bondar NP, Merkulova TI (2016) Brain-derived neurotrophic factor and early-life stress: multifaceted interplay. J Biosci 41: 751-758. https://doi.org/10.1007/s12038-016-9648-3
    [62] Alviña K, JodeiriFarshbaf M, Mondal AK (2021) Long term effects of stress on hippocampal function: emphasis on early life stress paradigms and potential involvement of neuropeptide Y. J Neurosci Res 99: 57-66. https://doi.org/10.1002/jnr.24614
    [63] Yam KY, Ruigrok SR, Ziko I, et al. (2017) Ghrelin and hypothalamic NPY/AgRP expression in mice are affected by chronic early-life stress exposure in a sex-specific manner. Psychoneuroendocrinology 86: 73-77. https://doi.org/10.1016/j.psyneuen.2017.09.006
    [64] Guerrini R, Salvadori S, Rizzi A, et al. (2010) Neurobiology, pharmacology, and medicinal chemistry of neuropeptide S and its receptor. Med Res Rev 30: 751-777. https://doi.org/10.1002/med.20180
    [65] Okamura N, Reinscheid RK (2007) Neuropeptide S: a novel modulator of stress and arousal. Stress 10: 221-226. https://doi.org/10.1080/10253890701248673
    [66] Chauveau F, Claverie D, Lardant E, et al. (2020) Neuropeptide S promotes wakefulness through the inhibition of sleep-promoting ventrolateral preoptic nucleus neurons. Sleep 43: zsz189. https://doi.org/10.1093/sleep/zsz189
    [67] Ionescu IA, Dine J, Yen YC, et al. (2012) Intranasally administered neuropeptide S (NPS) exerts anxiolytic effects following internalization into NPS receptor-expressing neurons. Neuropsychopharmacology 37: 1323-1337. https://doi.org/10.1038/npp.2011.317
    [68] Lukas M, Bredewold R, Neumann ID, et al. (2010) Maternal separation interferes with developmental changes in brain vasopressin and oxytocin receptor binding in male rats. Neuropharmacology 58: 78-87. https://doi.org/10.1016/j.neuropharm.2009.06.020
    [69] Nauta WJ, Domesick VB (1978) Crossroads of limbic and striatal circuitry: hypothalamo-nigral connections. [In] Limbic mechanisms. Boston, MA.: Springer 75-93. https://doi.org/10.1007/978-1-4757-0716-8_6
    [70] Daniels WMU, Pietersen CY, Carstens ME, et al. (2004) Maternal separation in rats leads to anxiety-like behavior and a blunted ACTH response and altered neurotransmitter levels in response to a subsequent stressor. Metab Brain Dis 19: 3-14. https://doi.org/10.1023/B:MEBR.000027412.19664.b3
    [71] Valentino RJ, Van Bockstaele E (2001) Opposing regulation of the locus coeruleus by corticotropin-releasing factor and opioids. Psychopharmacology 158: 331-342. https://doi.org/10.1007/s002130000673
    [72] Valentino RJ, Van Bockstaele E (2008) Convergent regulation of locus coeruleus activity as an adaptive response to stress. Eur J Pharmacol 583: 194-203. https://doi.org/10.1016/j.ejphar.2007.11.062
    [73] Valentino RJ, Foote SL, Page ME (1993) The locus coeruleus as a site for integrating corticotropin-releasing factor and noradrenergic mediation of stress responses. An NY Acad Sci 697: 173-188. https://doi.org/10.1111/j.1749-6632.1993.tb49931.x
    [74] Chang S, Deussing JM (2021) Corticotropin-Releasing Hormone in the Paraventricular Nucleus of the Hypothalamus—Beyond Hypothalamic–Pituitary–Adrenal Axis Control. [In] Neuroanatomy of Neuroendocrine Systems. Cham.: Springer 231-250. https://doi.org/10.1007/978-3-030-86630-3_9
    [75] Jüngling K, Liu X, Lesting J, et al. (2012) Activation of neuropeptide S-expressing neurons in the locus coeruleus by corticotropin-releasing factor. J Physiol 590: 3701-3717. https://doi.org/10.1113/jphysiol.2011.226423
    [76] Ross JA, Van Bockstaele EJ (2021) The locus coeruleus-norepinephrine system in stress and arousal: unraveling historical, current, and future perspectives. Front Psychiatry 11: 1581. https://doi.org/10.3389/fpsyt.2020.601519
    [77] Liu D, Caldji C, Sharma S, et al. (2000) Influence of neonatal rearing conditions on stress-induced adrenocorticotropin responses and norepinepherine release in the hypothalamic paraventricular nucleus. J Neuroendocrinol 12: 5-12. https://doi.org/10.1046/j.1365-2826.2000.00422.x
    [78] Matthews K, Dalley JW, Matthews C, et al. (2001) Periodic maternal separation of neonatal rats produces region-and gender-specific effects on biogenic amine content in postmortem adult brain. Synapse 40: 1-10. https://doi.org/10.1002/1098-2396(200104)40:1<1::AID-SYN1020>3.0.CO;2-E
    [79] Bhatnagar S, Vining C, Denski KAI (2004) Regulation of chronic stress-induced changes in hypothalamic-pituitary-adrenal activity by the basolateral amygdala. Ann NY Acad Sci 1032: 315-319. https://doi.org/10.1196/annals.1314.050
    [80] LeDoux J (2007) The amygdala. Curr Biol 17: 868-874. https://europepmc.org/article/med/17956742
    [81] Keshavarzi S, Sullivan RK, Ianno DJ, et al. (2014) Functional properties and projections of neurons in the medial amygdala. J Neurosci 34: 8699-8715. https://doi.org/10.1523/JNEUROSCI.1176-14.2014
    [82] Grund T, Neumann ID (2018) Neuropeptide S induces acute anxiolysis by phospholipase C-dependent signaling within the medial amygdala. Neuropsychopharmacology 43: 1156-1163. https://doi.org/10.1038/npp.2017.169
    [83] Plotsky PM, Owens MJ, Nemeroff CB (1998) Psychoneuroendocrinology of depression: hypothalamic-pituitary-adrenal axis. Psychiatr Clin N Am 21: 293-307. https://doi.org/10.1016/S0193-953X(05)70006-X
    [84] Corradi PF, Corradi RB, Greene LW (2016) Physiology of the hypothalamic pituitary gonadal axis in the male. Urol Clin 43: 151-162. https://doi.org/10.1016/j.ucl.2016.01.001
    [85] Ortiga-Carvalho TM, Chiamolera MI, Pazos-Moura CC, et al. (2011) Hypothalamus-pituitary-thyroid axis. ComprPhysiol 6: 1387-1428. https://doi.org/10.1002/cphy.c150027
    [86] Veenema AH, Blume A, Niederle D, et al. (2006) Effects of early life stress on adult male aggression and hypothalamic vasopressin and serotonin. Eur J Neurosci 24: 1711-1720. https://doi.org/10.1111/j.1460-9568.2006.05045.x
    [87] Veenema AH, Neumann ID (2009) Maternal separation enhances offensive play-fighting, basal corticosterone and hypothalamic vasopressin mRNA expression in juvenile male rats. Psychoneuroendocrinology 34: 463-467. https://doi.org/10.1016/j.psyneuen.2008.10.017
    [88] Lukas M, Neumann ID (2012) Nasal application of neuropeptide S reduces anxiety and prolongs memory in rats: social versus non-social effects. Neuropharmacology 62: 398-405. https://doi.org/10.1016/j.neuropharm.2011.08.016
    [89] VanBodegom M, Homberg JR, Henckens MJ (2017) Modulation of the hypothalamic-pituitary-adrenal axis by early life stress exposure. Front Cell Neurosci 11: 87. https://doi.org/10.3389/fncel.2017.00087
    [90] Bombail V (2019) Perception and emotions: on the relationships between stress and olfaction. Appl BehavAnim Sci 212: 98-108. https://doi.org/10.1016/j.applanim.2018.12.013
    [91] Mikrouli E, Wörtwein G, Soylu R, et al. (2011) Increased numbers of orexin/hypocretin neurons in a genetic rat depression model. Neuropeptides 45: 401-406. https://doi.org/10.1016/j.npep.2011.07.010
    [92] Albert PR, Vahid-Ansari F (2019) The 5-HT1A receptor: signaling to behavior. Biochimie 161: 34-45. https://doi.org/10.1016/j.biochi.2018.10.015
    [93] Gilbert F, Brazell C, Tricklebank MD, et al. (1988) Activation of the 5-HT1A receptor subtype increases rat plasma ACTH concentration. Eur J Pharmacol 147: 431-439. https://doi.org/10.1016/0014-2999(88)90178-1
    [94] Fletcher A, Forster EA, Bill DJ, et al. (1995) Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res 73: 337-353. https://doi.org/10.1016/0166-4328(96)00118-0
    [95] Valentino RJ, Foote SL, Aston-Jones G (1983) Corticotropin-releasing factor activates noradrenergic neurons of the locus coeruleus. Brain Res 270: 363-367. https://doi.org/10.1016/0006-8993(83)90615-7
    [96] Pickel VM, Joh TH, Reis DJ (1977) A serotonergic innervation of noradrenergic neurons in nucleus locus coeruleus: demonstration by immunocytochemical localization of the transmitter specific enzymes tyrosine and tryptophan hydroxylase. Brain Res 131: 197-214. https://doi.org/10.1016/0006-8993(77)90515-7
    [97] Steinbusch HWM (1984) Serotonin-immunoreactive neurons and their projections in the CNS. Handbook of Chemical Neuroanatomy, Chemical Transmitter Receptors in the CNS, 3, Part II : 68-118. https://cir.nii.ac.jp/crid/1572824499186806784
    [98] Leysen JE (2004) 5-HT2 receptors. CurrDrug Targets 3: 11-26. https://doi.org/10.2174/1568007043482598
    [99] Rossi DV, Burke TF, Hensler JG (2008) Differential regulation of serotonin-1A receptor-stimulated [35S] GTPγS binding in the dorsal raphe nucleus by citalopram and escitalopram. Eur J Pharmacol 583: 103-107. https://doi.org/10.1016/j.ejphar.2008.01.022
    [100] Segal M (1979) Serotonergic innervation of the locus coeruleus from the dorsal raphe and its action on responses to noxious stimuli. J Physiol 286: 401-415. https://doi.org/10.1113/jphysiol.1979.sp012628
    [101] Van Bockstaele EJ (2000) Multiple substrates for serotonergic modulation of rat locus coeruleus neurons and relationships with kainate receptors. Brain Res Bull 51: 433-442. https://doi.org/10.1016/S0361-9230(99)00267-1
    [102] West CH, Ritchie JC, Boss-Williams KA, et al. (2009) Antidepressant drugs with differing pharmacological actions decrease activity of locus coeruleus neurons. Int J Neuropsychopharmacol 12: 627-641. https://doi.org/10.1017/S1461145708009474
    [103] Bobker DH, Williams JT (1989) Serotonin agonists inhibit synaptic potentials in the rat locus ceruleus in vitro via 5-hydroxytryptamine1A and 5-hydroxytryptamine1B receptors. J Pharmacol Exp Ther 250: 37-43. https://europepmc.org/article/med/2526217
    [104] Holanda VA, Oliveira MC, Souza LS, et al. (2019) Dopamine D1 and D2 receptors mediate neuropeptide S-induced antinociception in the mouse formalin test. Eur J Pharmacol 859: 172557. https://doi.org/10.1016/j.ejphar.2019.172557
    [105] Nitz D, Siegel J (1997) GABA release in the dorsal raphe nucleus: role in the control of REM sleep. Am J PhysiolRegulIntegr Comp Physiol 273: 451-455. https://doi.org/10.1152/ajpregu.1997.273.1.R451
    [106] Soya S, Sakurai T (2020) Orexin as a modulator of fear-related behavior: hypothalamic control of noradrenaline circuit. Brain Res 1731: 146037. https://doi.org/10.1016/j.brainres.2018.11.032
    [107] Tobinski AM, Rappeneau V (2021) Role of the Neuropeptide S System in Emotionality, Stress Responsiveness and Addiction-Like Behaviours in Rodents: Relevance to Stress-Related Disorders. Pharmaceuticals 14: 780. https://doi.org/10.3390/ph14080780
    [108] Tillage RP, Foster SL, Lustberg D, et al. (2021) Co-released norepinephrine and galanin act on different timescales to promote stress-induced anxiety-like behavior. Neuropsychopharmacology 46: 1535-1543. https://doi.org/10.1038/s41386-021-01011-8
    [109] Millan MJ, Dekeyne A, Papp M, et al. (2001) S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 298: 581-591. https://jpet.aspetjournals.org/content/298/2/565.short
    [110] Rossi DV, Valdez M, Gould GG, et al. (2006) Chronic administration of venlafaxine fails to attenuate 5-HT1A receptor function at the level of receptor-G protein interaction. Int J Neuropsychopharmacol 9: 393-406. https://doi.org/10.1017/S1461145705005754
    [111] Béïque JC, Blier P, de Montigny C, et al. (2000) Potentiation by (-) pindolol of the activation of postsynaptic 5-HT1A receptors induced by venlafaxine. Neuropsychopharmacology 23: 294-306. https://doi.org/10.1016/S0893-133X(00)00112-3
    [112] Niimi M (2006) Centrally administered neuropeptide S activates orexin-containing neurons in the hypothalamus and stimulates feeding in rats. Endocrine 30: 75-79. https://doi.org/10.1385/ENDO:30:1:75
    [113] Cannella N, Kallupi M, Ruggeri B, et al. (2013) The role of the neuropeptide S system in addiction: focus on its interaction with the CRF and hypocretin/orexin neurotransmission. Prog Neurobiol 100: 48-59. https://doi.org/10.1016/j.pneurobio.2012.09.005
    [114] Berlau DJ, McGaugh JL (2006) Enhancement of extinction memory consolidation: the role of the noradrenergic and GABAergic systems within the basolateral amygdala. Neurobiol Learn Mem 86: 123-132. https://doi.org/10.1016/j.nlm.2005.12.008
    [115] Roozendaal B, Castello NA, Vedana G, et al. (2008) Noradrenergic activation of the basolateral amygdala modulates consolidation of object recognition memory. Neurobiol Learn Mem 90: 576-579. https://doi.org/10.1016/j.nlm.2008.06.010
    [116] Han RW, Xu HJ, Wang P, et al. (2014) Neuropeptide S interacts with the basolateral amygdala noradrenergic system in facilitating object recognition memory consolidation. Neurobiol Learn Mem 107: 32-36. https://doi.org/10.1016/j.nlm.2013.10.010
    [117] Guarnieri LO, Pereira-Caixeta AR, Medeiros DC, et al. (2020) Pro-neurogenic effect of fluoxetine in the olfactory bulb is concomitant to improvements in social memory and depressive-like behavior of socially isolated mice. Transl Psychiatry 10: 1-14. https://doi.org/10.1038/s41398-020-0701-5
    [118] Zhang J, Dennis KA, Darling RD, et al. (2013) Neonatal citalopram exposure decreases serotonergic fiber density in the olfactory bulb of male but not female adult rats. Front Cell Neurosci 7: 67. https://doi.org/10.3389/fncel.2013.00067
    [119] Thase ME, Shelton RC, Khan A (2006) Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard-and higher-dosing strategies. J Clin Psychopharmacol 26: 250-258. https://doi.org/10.1097/01.jcp.0000219922.19305.08
    [120] Engelmann J, Wagner S, Solheid A, et al. (2021) Tolerability of high-dose venlafaxine after switch from escitalopram in nonresponding patients with major depressive disorder. J Clin Psychopharmacol 41: 62-66. https://doi.org/10.1097/JCP.0000000000001312
    [121] Bonapersona V, Kentrop J, Van Lissa CJ, et al. (2019) The behavioral phenotype of early life adversity: A 3-level meta-analysis of rodent studies. NeurosciBiobehav Rev 102: 299-307.
    [122] Bonapersona V, Hoijtink H, Sarabdjitsingh RA, et al. (2021) Increasing the statistical power of animal experiments with historical control data. Nat Neurosci 24: 470-477. https://doi.org/10.1038/s41593-020-00792-3
    [123] Button KS, Ioannidis J, Mokrysz C, et al. (2013) Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci 14: 365-376. https://doi.org/10.1038/nrn3475
  • neurosci-09-03-022-s001.pdf
  • Reader Comments
  • © 2022 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(2582) PDF downloads(164) Cited by(5)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog